INSIDE THIS ISSUE

- **Highlights of Protocol Changes**
- **Benefit Drug List**
- **Protocol Update** – BRAJCAF, BRAVCAF, BRINFCAF, BRLA2, ULYALEM
- **Reimbursement Forms** – Undesignated Indication Request
- **Cancer Management Manual**
- **Pre-Printed Order Update** – BRAJCEF, BRAVDOC, BRINFCEF, BRLACEF, GUVEIP, GUVIP2
- **Patient Education** – Gefitinib (Iressa®), PSA Screening for Prostate Cancer, LYABVD
- **Cancer Drug Manual**
- **Nursing Practice** - Supporting Continuing Competence In Chemotherapy
- **Focus On** – Adjuvant Oxaliplatin in Colorectal Cancer
- **Provincial Systemic Therapy Program Policies**
- **Library/Cancer Information Centre**
- **Continuing Education** – BC Cancer Agency Annual Cancer Conference 2003

FAX request form and IN TOUCH phone list are provided if additional information is needed.

**HIGHLIGHTS OF PROTOCOL CHANGES**

The Breast Tumour Group has revised the fluorouracil dose in the CAF regimen (cyclophosphamide, doxorubicin [Adriamycin], fluorouracil) from the current 600 mg/m² to 500 mg/m². The latter dose was used in the original clinical trial (Bennett JM, et al. J Clin Oncol 1988;6(10):1611-20). The protocols affected by this change include CAF regimen used in locally advanced (BRLA2), inflammatory (BRINFCAF) and metastatic (BRAVCAF) breast cancer, as well as the adjuvant setting (BRAJCAF). Patients currently already on CAF regimens do not need to have their dose reduced.

**BENEFIT DRUG LIST**

The current Benefit Drug List, Class II forms and Undesignated Indication Application forms are available on the BC Cancer Agency website (www.bccancer.bc.ca) under Health Professionals Info, Chemotherapy Protocols, Frequently Used Forms.

**LIST OF NEW AND REVISED PROTOCOLS**

INDEX to BC Cancer Agency Protocol Summaries revised monthly (include tumour group, protocol code, indication, drugs, last revision date and version). Protocol codes for treatments requiring “Undesignated Indication” approval prior to use are prefixed with the letter U.

- **BRAJCAF** revised (fluorouracil dose reduced, reference added): Adjuvant therapy for breast cancer using cyclophosphamide, doxorubicin and fluorouracil
- **BRAVCAF** revised (fluorouracil dose reduced, reference added): Palliative therapy for metastatic breast cancer using cyclophosphamide, doxorubicin and fluorouracil
- **BRINFCAF** revised (fluorouracil dose reduced, reference added): Inflammatory breast cancer using cyclophosphamide, doxorubicin and fluorouracil
- **BRLA2** revised (fluorouracil dose reduced, reference added): Locally advanced breast cancer using cyclophosphamide, doxorubicin and fluorouracil
- **ULYALEM** revised (corticosteroids premedications): Treatment of fludarabine-refractory B-chronic lymphocytic leukemia (B-CLL) and T-prolymphocytic leukemia (T-PLL) with alemtuzumab

Protocols are available on the BC Cancer Agency website ([www.bccancer.bc.ca](http://www.bccancer.bc.ca)) under Health Professionals Info, Chemotherapy Protocols.

### Reimbursement Forms

**Undesignated Indication Form** has been reformatted. Copies of the form can be obtained via faxback and electronic version of the form is available on the BC Cancer Agency website ([www.bccancer.bc.ca](http://www.bccancer.bc.ca)) under Health Professionals Info, Chemotherapy Protocols, Frequently Used Forms.

### Cancer Management Guidelines

**Empiric Treatment of Febrile Neutropenia** A new guideline on the empiric management of febrile neutropenia in patients with solid tumours has been developed with input from the Medical Oncology and Antibiotic Subcommittee of the BC Cancer Agency. This is based on a compilation of published guidelines and current practice. Similar guidelines are also available for bone marrow transplant patients and pediatric patients.

The guidelines on treatment of febrile neutropenia are available on the BC Cancer Agency website ([www.bccancer.bc.ca](http://www.bccancer.bc.ca)) under Health Professionals, Cancer Management Guidelines, Supportive Care, Febrile Neutropenia.

**Prostate Cancer Screening** A new patient information pamphlet on the use of prostate specific antigen test (PSA) to detect prostate cancer is now available as a patient resource. For more information, see under the Patient Education section in this issue of the Update or go to our website at [www.bccancer.bc.ca/PSAScreening](http://www.bccancer.bc.ca/PSAScreening).

The Cancer Management Guidelines are available on the BC Cancer Agency website ([www.bccancer.bc.ca](http://www.bccancer.bc.ca)) under Health Professionals Info, Cancer Management Guidelines.

### Pre-Printed Order Update

Pre-printed orders should always be checked with the most current BC Cancer Agency protocol summaries. The BC Cancer Agency Vancouver Centre has prepared chemotherapy pre-printed orders, which can be used as a guide for reference. An index to the orders can be obtained by Fax-back.

- **BRAJCEF** revised (CBC and diff in Labs section): Adjuvant therapy for breast cancer using Cyclophosphamide, Epirubicin and Fluorouracil
- **BRAVDOC** revised (note added regarding non-PVC equipment): Palliative therapy for metastatic breast cancer using docetaxel (Taxotere®)
- **BRINFCEF** revised (CBC and diff in Labs section): Therapy for inflammatory breast cancer using cyclophosphamide, epirubicin and fluorouracil
- **BRLACEF** revised (CBC and diff in Labs section): Therapy for locally advanced breast cancer using cyclophosphamide, epirubicin and fluorouracil
- **GUVEIP** revised (mesna dosing): Nonseminoma consolidation/salvage protocol for germ cell cancer using vinblastine, cisplatin, ifosfamide and mesna
- **GUVIP2** revised (mesna dosing): Nonseminoma consolidation/salvage protocol (synonyms: GU-88-02) using etoposide, cisplatin, ifosfamide, mesna

### Patient Education

**Gefitinib (Iressa®, ZD 1839)** This patient information handout has been revised to include the generic name of “gefitinib” of the drug and cautions on rare pulmonary toxicity. For more information, please refer to the August 2002 issue ([Vol 5, No 8](http://www.bccancer.bc.ca)) of the Systemic Therapy Update newsletter.

Patient information handouts for cancer drugs are available on the BC Cancer Agency website ([www.bccancer.bc.ca](http://www.bccancer.bc.ca)) under Health Professionals Info, Cancer Drug Manual, Drug Information for the Patient.
For treatment protocol specific information, go to the BC Cancer Agency website (www.bccancer.bc.ca) under Health Professionals Info, Chemotherapy Protocols, Information for the Patient.

**PSA Screening for Prostate Cancer**

To assist British Columbia men in making informed decisions about testing for prostate cancer, the BC Cancer Agency has created a pamphlet – "The Pros and Cons of PSA Screening for Prostate Cancer" – outlining the risks and benefits of testing.

The blood test commonly used to detect the presence of prostate cancer – the prostate specific antigen test (PSA) – is a controversial screening tool. There are valid reasons for and against the decision to have a PSA test. Currently, there is no clear agreement among health care experts that a PSA test offers a definitive answer about what a man should do. Before requesting the test, the BC Cancer Agency believes that men should be informed of the pros and cons. The pamphlet, developed in collaboration with the Vancouver Prostate Support and Awareness Group, offers information about prostate cancer, other prostate conditions, reasons to test, and reasons not to test.

**PSA Screening for Prostate Cancer (cont’d)**

As part of Prostate Cancer Awareness Week (September 15 to 21), the BC Cancer Agency has started distributing 50,000 of these decision-making guides to family physician offices across the province. The Agency recommends that men who are aged 50 to 70 discuss the issues with their family doctor and make their own decision whether to be tested or not.

The PSA Screening Pamphlet is available on the BC Cancer Agency website (www.bccancer.bc.ca) under a direct link of www.bccancer.bc.ca/PSAScreening. Printed copies of the brochure may be obtained from:

Attention: Shirlyn Baskette  
BC Cancer Foundation  
200-601 West Broadway  
Vancouver V5Z 4C2  
Tel: 1-888 906-2873 or email sbaskette@bccancer.bc.ca

---

**CANCER DRUG MANUAL**

The Cancer Drug Manual is available on the BC Cancer Agency website www.bccancer.bc.ca/cdm/.

---

**NURSING PRACTICE**

**Supporting Continuing Competence In Chemotherapy**

At the BC Cancer Agency, our goal is to support all chemotherapy certified nurses to maintain and continue their competency in the administration of chemotherapy.

Key aspects of continuing competency are:
- adequate opportunities to apply the knowledge and skill of chemotherapy administration, and
- access to ongoing educational opportunities to support current chemotherapy practice.

Information about BCCA Nursing’s initiative to support your continuing competence in chemotherapy has been mailed to you and your manager. If you have not received your information letter by 15th of October, please contact Isabel Lundie by e-mail (ilundie@bccancer.bc.ca) or by phone at 1-800-663-3333, local 2623.

---

**FOCUS ON ADJUVANT OXALIPLATIN IN COLORECTAL CANCER**

Recent data presented at the 2003 American Society of Clinical Oncology meeting, suggested that combination oxaliplatin-based regimens may have a role in the adjuvant therapy of colorectal cancer.\(^1\,^2\) The Multicenter International Study of Oxaliplatin/5FU-LV in the Adjuvant Treatment of Colon Cancer (MOSAIC) involved 2248 patients with completely resected stage II (40%) or III (60%) colon cancer. Patients were randomized to receive either adjuvant leucovorin 200 mg/m\(^2\) as a 2 hour infusion, fluorouracil 400 mg/m\(^2\) bolus and 600 mg/m\(^2\) over 22-hours as a continuous infusion on days 1 and 2 or the identical regimen with the addition of oxaliplatin 85 mg/m\(^2\), given on day 1 only.\(^3\) Both regimens were repeated every 14 days for a total of 12 cycles.

A significantly higher 3-year disease free survival was seen with the oxaliplatin-based regimen (77.8% vs. 72.9%, hazard ratio [HR] 0.77 [0.65-0.92], p < 0.01). Subgroup analyses showed significant benefits in stage III patients...
(71.8% vs. 65.5%, HR 0.76 [0.62-0.92]) and a trend towards increased survival with stage II patients (86.6% vs. 83.9%, HR 0.82 [0.57-1.17]). All cause mortality of either regimen was 0.5% and febrile neutropenia was seen in less than 2% of the patients. The oxaliplatin-based regimen was associated with more grade ¾ neutropenia (41.0% vs. 4.7%) and peripheral sensory neuropathy (12.4% vs. 1%).

The implications of these promising results await the publication of the overall survival data from this or other adjuvant therapy trials. Therefore, at this time adjuvant combination regimens are not recommended by the BCCA Gastrointestinal Tumour Group and are not funded by the BCCA. The fluorouracil-leucovorin regimen (GIFFAD) remains the recommended adjuvant chemotherapy for stage III and selected high risk stage II colorectal cancer patients. For more details, see the BCCA Cancer Management Guidelines.

References:

PROVINCIAL SYSTEMIC THERAPY
PROGRAM POLICIES

BC Cancer Agency Systemic Therapy Policies are available on the BC Cancer Agency website (www.bccancer.bc.ca) under Health Professionals Info, Chemotherapy Protocols, Policies and Procedures.

LIBRARY/CANCER INFORMATION CENTRE

Unconventional Cancer Therapies Manual is available on the BC Cancer Agency website www.bccancer.bc.ca under Patient/Public Info, Unconventional Therapies. The manual consists of 46 short monographs on the more commonly used unconventional cancer therapies (e.g., Essiac, vitamins, teas, shark cartilage) and includes tips for the patient and family on how unconventional therapies can be evaluated. For each therapy the manual provides proponent/advocate claims, as Unconventional Cancer Therapies Manual (cont’d) well as evidence-based evaluation/critique quotations from the literature.

This manual is currently being revised and the Fourth Edition will be published in the near future.

CONTINUING EDUCATION

British Columbia Cancer Agency Annual Cancer Conference 2003 This year’s conference will be held from November 27 to 29, 2003 at The Fairmont Vancouver Hotel in Vancouver.

The Partners in Cancer Care meeting will be held on Thursday, November 27. The meeting will focus on The Evolving Regional, Provincial and BC Cancer Agency Collaboration in Planning and Delivery of Cancer Care, with representation from health professionals who care for cancer patients throughout British Columbia.

The focus of the Clinical-Scientific meetings on Friday and Saturday will be on “Risk Reduction in Cancer Incidence”. This is open to all healthcare professionals and is an academic evidence-based exploration of new scientific insights that hold potential to advance cancer care.

The Provincial Oncology Professionals education and business meetings will be held on all three days of the conference for the following disciplines:

<table>
<thead>
<tr>
<th>Friday, November 27</th>
<th>Saturday, November 28</th>
<th>Sunday, November 29</th>
</tr>
</thead>
<tbody>
<tr>
<td>Nursing</td>
<td>Nursing</td>
<td>Family Practice</td>
</tr>
<tr>
<td>Nutrition</td>
<td>Nutrition</td>
<td>Pharmacy</td>
</tr>
<tr>
<td>Pathology</td>
<td>Psychosocial Oncology</td>
<td>Pediatric Oncology</td>
</tr>
<tr>
<td>Psychosocial Oncology</td>
<td></td>
<td>Oral Oncology/Dentistry</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Radiation Oncology</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Radiation Therapy</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Surgical Oncology</td>
</tr>
</tbody>
</table>
**Call for Abstracts** Poster Presentations **Deadline for submission is October 17, 2003.** Details on abstract submission can be found on “Annual Cancer Conference 2003” section on our website: [www.bccancer.bc.ca](http://www.bccancer.bc.ca)

**Early bird registration (before October 17)** is $100. Thereafter, the cost of registration is $150. You can also register on-site on the day of the conference for $200.

For more information about the conference, click on the link: [http://www.bccancer.bc.ca/HPI/ACC2003](http://www.bccancer.bc.ca/HPI/ACC2003) or call (604) 877-6098 local 2744.

**Editorial Review Board**

Mário de Lemos, MSc, PharmD (Editor)
Cicely Bryce, MD
Johanna Den Duyf, MA
Karen Janes, MSN
Beth Morrison, MLS
Jaya Venkatesh, MHA
Laurel Kovacic, BSc (Pharm)
Gigi Concon (Secretary)
BC CANCER AGENCY SYSTEMIC THERAPY UPDATE REQUEST FORM

FAX (604) 877-0585
bulletin@bccancer.bc.ca

TO SUBSCRIBE: FAX OR EMAIL YOUR REQUEST OR CALL @ 877-6098 LOCAL 2247
FOR URGENT REQUESTS PLEASE CALL (604) 877-6098 LOCAL 2247
OR TOLL-FREE IN BC 1-800-663-3333 LOCAL 2247
PLEASE FEEL FREE TO MAKE COPIES FOR YOUR COLLEAGUES

I WOULD PREFER TO RECEIVE THIS INFORMATION VIA:

☐ E-mail (Word 6.0) @

☐ Fax ( ) Attn:

UPDATES Please ☑ Fax-Back information below:

***Most items have been hyperlinked for easy access***

☐ All items for OCTOBER 2003

Cancer Drug Manual Monographs: (also available on our website www.bccancer.bc.ca)
Patient Education Handout: (also available on our website www.bccancer.bc.ca)

☐ LYABVD

Pre-printed Orders:

☐ BRAJCEF ☐ BRINFCEF ☐ GUVEIP
☐ BRAVDOC ☐ BRLACEF ☐ GUVIP2

Protocol Summaries: (also available on our website www.bccancer.bc.ca)

Index of Protocol Summaries ☐ Index_NT ☐ Index_W6

☐ BRAJCAF ☐ BRAVCAF ☐ BRINFCAF ☐ BRLA2 ☐ ULYALEM

Provincial Systemic Therapy Program Policies

Reimbursement (also available on our website www.bccancer.bc.ca)

☐ Benefit Drug List (01 August 2003)
☐ Class 2 Form (01 August 2003)
☐ Undesignated Indication Form (01 October 2003 - reformatted)

Systemic Therapy Update Index (also available on our website www.bccancer.bc.ca)

☐ Jan-Dec 2000
☐ Jan-Dec 2001
☐ Jan-Dec 2002
☐ Jan-Jun 2003